John D. Bonnet

2.2k citations

41 papers · 1.7k indexed · h-index 22

Impact in

Hematology top 1%
- Multiple Myeloma Research and Treatments
Oncology top 2%
- Cancer Treatment and Pharmacology
- Peptidase Inhibition and Analysis
- Drug Transport and Resistance Mechanisms
- Colorectal Cancer Treatments and Studies

Papers in

Hematology 20
- Multiple Myeloma Research and Treatments 17
Oncology 25
- Cancer Treatment and Pharmacology 12
- Peptidase Inhibition and Analysis 5
- Colorectal Cancer Treatments and Studies 3

Co-authors: Arthur Haut Raymond Alexanian Edmund A. Gehan James S. Hewlett Raymond W. Monto Stanley P. Balcerzak Dennis O. Dixon James K. Weick
Journals: Cancer (12 papers)Investigational New Drugs (6 papers)Journal of Clinical Oncology (4 papers)JNCI Journal of the National Cancer Institute (1 paper)JAMA (1 paper)
Partner nations: United States Portugal Egypt

In The Last Decade

John D. Bonnet

39 papers receiving 1.5k citations

Peers

Countries citing papers authored by John D. Bonnet

Since Specialization

Citations

This map shows the geographic impact of John D. Bonnet's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John D. Bonnet with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John D. Bonnet more than expected).

Fields of papers citing papers by John D. Bonnet

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John D. Bonnet. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John D. Bonnet. The network helps show where John D. Bonnet may publish in the future.

Co-authorship network

The 25 scholars most cited alongside John D. Bonnet, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with John D. Bonnet Line = papers co-authored together John D. Bonnet links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Timing and Outcomes of Palliative Care Integration Into Care of Adolescents and Young Adults With Advanced Cancer JCO Oncology Practice ·John D. Bonnet, Rayella Stevens, Hajime Uno, Lanfang Xu, Cecile A. Laurent, 哈艳平, S V Moskalenko, C. K. morley, Robert Cooper, Joshua R. Lakin, Cinthya Fabiola Zamorano Vilar, 陸雄松吉, Andrea Altschuler, Lawrence H. Kushi, Chun Chao, Lori Wiener, Jennifer W. Mack	2025	0
2	A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A southwest oncology group study Cancer ·William S. Dalton, John J. Crowley, Xin Tian, Thomas M. Grogan, Leslie Rodgers Laufman, Geoffrey R. Weiss, John D. Bonnet	1995	131
3	Efficacy of prednisone in refractory multiple myeloma and measurement of glucocorticoid receptors Investigational New Drugs ·V. D. Gupta, E. Brad Thompson, Donna Stock-Novack, Sydney E. Salmon, H. Irving Pierce, John D. Bonnet, 峰由神山, 孙媛	1994	10
4	Phase II study of carboplatin (CBDCA) in refractory multiple myeloma Investigational New Drugs ·Bart Barlogie, John Crowley, Sydney E. Salmon, John D. Bonnet, James K. Weick, J. LIEU	1994	3
5	Evaluation of amonafide in refractory and relapsing multiple myeloma Anti-Cancer Drugs ·G. Natho, John Crowley, Sydney E. Salmon, LETICIA ARAUJO PRESCILLANO, Thomas J. Braun, John D. Bonnet	1991	3
6	Phase II Studies of Recombinant Human Tumor Necrosis Factor Alpha in Patients with Malignant Disease: A Summary of the Southwest Oncology Group Experience Journal of Immunotherapy ·Evan M. Hersh, Barbara Metch, Franco M. Muggia, Thomas D. Brown, Robert P. Whitehead, G. Thomas Budd, John J. Rinehart, E. David Crawford, John D. Bonnet, Brent C. Behrens	1991	49
7	Phase II evaluation of bisantrene in refractory multiple myeloma Investigational New Drugs ·Brian G.M. Durie, John Crowley, Charles A. Coltman, Robert Chapman, Shirley Araújo Cabral, John D. Bonnet, David A. Lipschitz, Ronald L. Stephens, Bruce D. Cheson	1991	4
8	Phase III Comparison of Doxorubicin and Dacarbazine Given by Bolus Versus Infusion in Patients With Soft-Tissue Sarcomas: A Southwest Oncology Group Study JNCI Journal of the National Cancer Institute ·Mark M. Zalupski, Barbara Metch, S P Balcerzak, William S. Fletcher, Robert Chapman, John D. Bonnet, Geoffrey R. Weiss, J.F. Ryan, Robert S. Benjamin, Larry Baker	1991	125
9	Phase II study of Fludarabine Phosphate in multiple myeloma Investigational New Drugs ·Eric H. Kraut, John J. Crowley, Michael R. Grever, LETICIA ARAUJO PRESCILLANO, John D. Bonnet, A. A. Auzin, Sydney E. Salmon	1990	32
10	Chemotherapy is superior to sequential hemibody irradiation for remission consolidation in multiple myeloma: a Southwest Oncology Group study. Journal of Clinical Oncology ·S. E. Salmon, Il'ya Medvedev, John Crowley, Sheikh M. Saeed, Patrick R. Finley, M. Milder, Laura F. Hutchins, Charles A. Coltman, John D. Bonnet, Bruce D. Cheson	1990	40
11	A phase II study of intravenous 6-thioguanine (NSC-752) in multiple myeloma Investigational New Drugs ·Mark Edelstein, John J. Crowley, Fred Valeriote, John D. Bonnet, I Takekuma, Noviana Cahya Anggraini, Sydney E. Salmon, Ziyi Zhang	1990	3
12	Aclacinomycin A in the treatment of multiple myeloma: A Southwest Oncology Group study Investigational New Drugs ·Chatchada Karanes, John Crowley, 윤정석, Bill L. Tranum, William J. Hicks, John D. Bonnet, Lyubica Dabich, Bruce W. Dana, Sydney E. Salmon	1990	3
13	Adjuvant therapy in large bowel adenocarcinoma: long-term results of a Southwest Oncology Group Study. Journal of Clinical Oncology ·Frank J. Panettiere, Phyllis J. Goodman, J J Costanzi, Anatolio B. Cruz, V. K. Vaitkevicius, Joseph D. McCracken, Robert Brownlee, Leslie R. Laufman, Ronald L. Stephens, John D. Bonnet	1988	61
14	Addition of cisplatin and bleomycin to vincristine-carmustine-doxorubicin-prednisone (VBAP) combination in the treatment of relapsing or resistant multiple myeloma: a Southwest Oncology Group study. PubMed ·John D. Bonnet, Raymond Alexanian, S. E. Salmon, Arthur Haut, Dennis O. Dixon	1984	6
15	Vincristine, BCNU, doxorubicin, and prednisone (VBAP) combination in the treatment of relapsing or resistant multiple myeloma: a Southwest Oncology Group study. PubMed ·John D. Bonnet, Raymond Alexanian, S. E. Salmon, R Bottomley, Mammo Amare, Arthur Haut, Dennis O. Dixon	1982	27
16	Phase II evaluation of maytansine in refractory non-Hodgkin's lymphoma: a Southwest Oncology Group study. PubMed ·V. Ratanatharathorn, H. Ye, Henry E. Wilson, John D. Bonnet, S E Rivkin, R. Bartoszyński	1982	2
17	cis-Dichlorodiamminepltinum(II) in adult patients: Southwest Oncology Group Studies. PubMed ·Ross W. Stephens, Charles A. Coltman, Arthur H. Rossof, Shasha Liu, Frank J. Panettiere, Muhyi Al‐Sarraf, Alberts Ds, John D. Bonnet	1980	9
18	Combination therapy for multiple myeloma Cancer ·Raymond Alexanian, Sydney E. Salmon, John D. Bonnet, Edmund A. Gehan, Arthur Haut, James K. Weick	1977	107
19	Correlation of Blood and Fecal Radioactivity JAMA ·John D. Bonnet	1962	3
20	Rate of loss of radioiron from mouse and man American Journal of Physiology-Legacy Content ·John D. Bonnet, Alan L. Orvis, Albert B. Hagedorn, Charles A. Owen	1960	10

About John D. Bonnet

John D. Bonnet is a scholar working on Hematology, Oncology, Radiological and Ultrasound Technology, Pulmonary and Respiratory Medicine and Cancer Research, having authored 41 papers that have together received 1.7k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (17 papers), Cancer Treatment and Pharmacology (12 papers), Cancer therapeutics and mechanisms (8 papers), Peptidase Inhibition and Analysis (5 papers), Colorectal and Anal Carcinomas (4 papers), Colorectal Cancer Treatments and Studies (3 papers), Cancer Genomics and Diagnostics (2 papers) and Gastric Cancer Management and Outcomes (2 papers). The work is most often cited by research in Hematology (745 citations), Oncology (1.0k citations), Genetics (149 citations), Molecular Biology (620 citations) and Gastroenterology (47 citations). John D. Bonnet has collaborated with scholars based in United States, Portugal and Egypt. Frequent co-authors include Arthur Haut, Raymond Alexanian, Edmund A. Gehan, James S. Hewlett, Raymond W. Monto, Stanley P. Balcerzak, Dennis O. Dixon, James K. Weick, Geoffrey R. Weiss and Ronald L. Stephens. Their work appears in journals such as Cancer, Investigational New Drugs, Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and JAMA.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact